Microglia are the resident immune cells of the central nervous system (CNS), acting as the brain's primary defense, surveillance, and cleanup cells. They play critical roles in development, injury, disease, and have emerged as central players in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders.
Microglia are unique innate immune cells that:
- Originate from yolk sac progenitors during embryonic development, distinct from bone marrow-derived macrophages[1]
- 自我更新 (self-renew) in the adult brain through local proliferation
- Survey the CNS environment continuously via dynamic process motility (~2.5 μm/hour)
- Respond rapidly to injury and infection with stereotypical morphological and molecular changes
- Prune synapses during development and adulthood, sculpting neural circuits
- Exist in multiple activation states ranging from surveying to disease-associated phenotypes
Microglia are the resident immune cells of the central nervous system:
- Cell Body: Small, elongated or spherical soma (5-10 μm)
- Processes: Highly ramified, dynamic processes that constantly survey the CNS parenchyma
- Morphological States:
- Ramified (surveying): Resting state with extensive branching
- Amoeboid: Activated, migratory state
- Gitter cells: Engulfed debris-containing cells
- Special Features: Express CX3CR1 receptor, CD45, Iba1, TMEM119
Microglial electrophysiological properties (distinct from neurons):
- Resting Membrane Potential: -20 to -10 mV (less negative than neurons)
- Ion Channels: Predominantly potassium channels (K+), some sodium channels upon activation
- Response to ATP: P2X/P2Y receptor-mediated calcium signaling and process extension
- Phagocytic Activity: Capacity for engulfment of synapses, debris, and pathogens
- Distribution: Throughout the CNS, including all brain regions and spinal cord
- Density Variations: Higher density in hippocampus, cortex, and basal ganglia
- Regional Specialization:
- White matter: Lower density
- Gray matter: Higher density
- Perivascular spaces: Specialized macrophage populations
| Taxonomy |
ID |
Name / Label |
| Cell Ontology (CL) |
CL:0000129 |
microglial cell |
- Morphology: microglial cell (source: Cell Ontology)
- Morphology can be inferred from Cell Ontology classification
- Parent Classification: Immune
- Full Lineage: Glial > Immune > Microglia
- Brain Regions: Widespread (all brain regions), Higher density in gray matter
¶ Origin and Development
Microglia arise from primitive macrophages in the embryonic yolk sac:
- Yolk sac progenitors (E7.5-9.5) seed the developing CNS
- Colonization of the brain parenchyma during embryogenesis
- Self-renewal through local proliferation in adulthood
- Domain organization — each microglia surveys a territory of ~20-30 μm
The transcription factor PU.1 and CSF1R are essential for microglial development. The adult microglia transcriptome comprises ~1,000 differentially expressed genes, with Tmem119, P2ry12, and Cx3cr1 as canonical markers[2].
¶ Surveillance and Homeostatic Functions
Resting microglia (now termed "surveying microglia") extend and retract processes:
- Process motility: 1-2 μm per minute
- Territorial coverage: Non-overlapping domains
- Response to ATP: P2Y12 receptor-mediated chemotaxis toward injury
- Calcium signaling: Spontaneous calcium waves in process tips
Microglia eliminate inappropriate synapses during development and adulthood:
- Complement-mediated pruning: C1q tagging, C3-CR3 pathway
- Phagocytic removal: MEGF10 and MERTK receptors
- Activity-dependent: More active synapses are preserved
- Developmental windows: Peak pruning in early postnatal period
Dysregulated synaptic pruning is implicated in neurodevelopmental (autism) and neurodegenerative (AD) conditions[3].
Microglia secrete growth factors supporting neuron survival:
- BDNF (Brain-Derived Neurotrophic Factor)
- GDNF (Glial Cell Line-Derived Neurotrophic Factor)
- IGF-1 (Insulin-Like Growth Factor 1)
In neurodegenerative conditions, microglia transition to a disease-associated phenotype:
- Triggered by: Amyloid-β, α-synuclein, TREM2 ligands
- Features: Downregulation of P2ry12, Tmem119; upregulation of Apoe
- Metabolic shift: Glycolysis enhancement
- Triggered by: Continued pathology, TREM2 activation
- Features: Upregulation of inflammation genes, lysosomal genes
- Phagocytic capacity: Increased but may be dysfunctional
- Iron accumulation: Ferritin upregulation
The DAM pathway is TREM2-dependent — loss-of-function TREM2 variants increase AD risk and impair microglial response to amyloid plaques[4].
Microglia attempt to clear amyloid-β through:
- Receptor-mediated phagocytosis: TREM2, CD36, SR-A
- Secreted proteases: MMPs, IDE
- NLRP3 inflammasome activation: IL-1β production
However, chronic activation leads to:
- Inflammasome hyperactivation: Excessive IL-1β, IL-18
- Phagocytic dysfunction: Impaired clearance despite increased uptake
- Pro-inflammatory phenotype: TNF-α, NOS2 upregulation
Microglia contribute to tau spread through:
- Inflammation-driven tau phosphorylation: GSK3β, CDK5 activation
- Tau uptake and release: Propagating pathology between neurons
- NLRP3 inflammasome: Accelerates tau aggregation
AD risk genes highlight microglial involvement:
- TREM2: Loss-of-function increases risk ~3-4x
- CD33: Sialic acid receptor affecting phagocytosis
- PLCG2: Phospholipase C gamma 2, immune signaling
- ABI3: Involved in TREM2 signaling[5]
Microglia in the substantia nigra are particularly responsive:
- High baseline inflammation: More primed than other regions
- Dopaminergic neuron susceptibility: Mitochondrial stress signals
- α-Synuclein clearance: Attempted but often ineffective
Microglia attempt to clear α-synuclein aggregates:
- TLR2/TLR4 recognition: Pattern recognition receptors
- Upregulation in PD: Increased TLR expression
- Impaired clearance: Accumulation leads to chronic activation
- Spread hypothesis: Microglia may propagate pathology
Chronic microglial activation in PD:
- Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6
- Oxidative stress: iNOS, NADPH oxidase
- Excitotoxicity: Glutamate transporter dysfunction
- Progressive cycle: Neuronal damage → more inflammation[6]
- Astrocyte-microglia crosstalk: Mutant SOD1 triggers
- Motor neuron vulnerability: Pro-inflammatory microenvironment
- TREM2 variants: Modify disease progression
- Demyelination: Active lesion microglia phagocytose myelin
- Remyelination failure: Pro-inflammatory environment blocks OPC differentiation
- EAE model: Microglia-driven disease
- TREM2 variants: Increase risk similar to AD
- Progranulin deficiency: Microglial lysosomal dysfunction
- Inflammation: Early and persistent
- Minocycline: Microglial activation inhibitor (clinical trials in ALS, AD)
- NSAIDs: COX inhibitors (mixed results in AD prevention)
- JAK-STAT inhibitors: Blocking inflammatory signaling
- TREM2 agonism: Enhancing DAM pathway
- CSF1R antagonists: Reducing microglial proliferation (e.g., pexidartinib)
- CB2 receptor agonists: Anti-inflammatory without psychoactive effects
- Phagocytosis enhancement: Clearing pathology
- Metabolic normalization: Mitochondrial function
- Iron chelation: Addressing ferroptosis in microglia
- Microglia transplantation: iPSC-derived microglia
- Gene therapy: Modifying microglial function
- Nanoparticle delivery: Targeted anti-inflammatory drugs[7]
¶ Key Proteins and Receptors
| Protein/Receptor |
Gene |
Function |
| TREM2 |
TREM2 |
Triggering receptor on myeloid cells 2 |
| CX3CR1 |
CX3CR1 |
Fractalkine receptor |
| P2RY12 |
P2RY12 |
ATP receptor, surveillance |
| TMEM119 |
TMEM119 |
Microglial marker |
| IBA1 |
AIF1 |
Ionized calcium-binding adapter |
| CD33 |
CD33 |
Sialic acid receptor |
| NLRP3 |
NLRP3 |
Inflammasome component |
| C1Q |
C1QA/B/C |
Complement component |
| CSF1R |
CSF1R |
Colony stimulating factor receptor |
- In vivo imaging: Two-photon microscopy of microglia
- Single-cell RNA-seq: Profiling activation states
- Spatial transcriptomics: Region-specific microglial phenotypes
- iPSC-derived microglia: Disease modeling
- PET imaging: TSPO tracers for microglial activation
¶ Role in Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP)
Microglial activation in CBS exhibits distinct patterns:
- Asymmetric cortical involvement: More pronounced microglial activation in the affected hemisphere
- Tau pathology correlation: 4R-tau isoforms trigger microglial responses
- Motor cortex involvement: Primary sensorimotor cortex shows dense microglial clustering
- White matter microglia: Activated microglia in degenerating white matter tracts
Mechanistic insights:
- TREM2 variants: Modify disease progression in CBS
- CBA (corticobasal degeneration): Tau filaments initiate microglial proliferation
- NLRP3 inflammasome: Elevated in CBS cortex, drives IL-1β production
- Complement activation: C1q and C3b deposition on degenerating synapses
Therapeutic implications:
- TREM2 agonists may enhance pathological clearance
- Anti-inflammatory approaches must balance immune clearance
- CSF1R modulation could reduce proliferating microglia
PSP shows prominent microglial involvement:
- Brainstem predilection: Substantia nigra, globus pallidus, subthalamic nucleus
- Tau-loaded neurons: Surrounded by activated microglia
- Glial tau pathology: Tau in astrocytes and oligodendrocytes triggers microglial response
Regional microglial patterns:
- Substantia nigra pars reticulata: High microglial density
- Globus pallidus interna: Tau pathology with microglial activation
- Superior colliculus: Midbrain involvement
- Frontal cortex: Progressive cortical involvement
Mechanistic connections:
- 4R-tau: Dominant isoform, unique microglial interactions
- MAPT H1 haplotype: Genetic risk factor affecting microglial responses
- Neuroinflammation: Chronic microglial activation drives progression
- Iron accumulation: Ferritin-laden microglia in PSP brains
Neuroimaging correlates:
- TSP0 PET: Elevated binding in PSP brainstem and basal ganglia
- CSF sTREM2: Biomarker of microglial activation
- Microglial priming: Age-related susceptibility
Therapeutic targeting:
- TREM2 modulation: Enhancing clearance of tau
- Iron chelation: Reducing microglial iron burden
- Anti-inflammatory strategies: JAK-STAT inhibitors
- GFAP-targeting: Modulating astrocyte-microglia crosstalk
¶ Common Mechanisms in CBS and PSP
Both CBS and PSP share microglial mechanisms:
- TREM2-dependent pathways: Genetic variants affect disease course
- NLRP3 inflammasome: Central inflammatory driver
- Complement-mediated synapse loss: Contributes to cognitive decline
- Iron dysregulation: Microglial iron accumulation
- Astrocyte-microglia crosstalk: Shared reactive phenotypes
¶ Research and Clinical Implications
Microglial biomarkers for CBS/PSP:
- Imaging: TSP0 PET for in vivo activation
- CSF markers: sTREM2, YKL-40, IL-1β
- Genetic testing: TREM2, PLGCG2 variants
- Therapeutic trials: TREM2 agonists, anti-inflammatory agents
Microglia are dynamic CNS sentinels essential for brain health and central to neurodegenerative disease pathogenesis. Their dual roles in protection and pathology make them attractive therapeutic targets. Understanding the balance between beneficial surveillance and harmful inflammation, particularly in the DAM pathway, offers opportunities for modulating microglial function in AD, PD, and related disorders.
Cell Ontology IDs: CL:0000129
Conservation Overview: Evolutionarily ancient immune cells. Present in all vertebrates. Human microglia show unique transcriptional signatures compared to mouse (TREM2, CX3CR1 variants).
Ortholog Mapping: TREM2, CX3CR1, P2RY12 highly conserved. Human-specific microglial genes include MERTK, PROS1.
Sources: Cell Ontology, PanglaoDB[1], Allen Cell Type Database
[1]: PanglaoDB: Cell type markers
Data for Microglia from the Allen Brain Atlas:
| Resource |
Description |
Link |
| Allen Human Brain Atlas |
Transcriptomic data across adult brain regions |
Access |
| BrainSpan |
Developmental brain transcriptome |
Access |
| Allen Cell Type Atlas |
Single-cell expression data |
Access |
| Allen Mouse Brain Atlas |
Mouse brain connectivity and expression |
Access |
Microglia are the resident immune cells of the central nervous system, playing critical roles in brain development, homeostasis, and neurodegeneration.
- TREM2 Signaling: Triggering receptor expressed on myeloid cells 2 (TREM2) recognizes amyloid plaques, triggers phagocytosis
- TLR Activation: Toll-like receptors (TLR2, TLR4) detect DAMPs, pathogen-associated molecular patterns
- Complement System: C1q, C3标记突触，参与突触修剪
| Pathway |
Role |
AD/PD Relevance |
| NF-κB |
Pro-inflammatory gene transcription |
Elevated in AD/PD brains |
| MAPK (p38, JNK) |
Stress response, cytokine production |
Neuronal death |
| STAT3 |
Anti-inflammatory response |
Dysregulated in neurodegeneration |
- Pro-inflammatory cytokines: IL-1β, IL-6, TNF-α, IL-18 released by activated microglia
- Chemokines: CCL2, CXCL10 recruit peripheral immune cells
- Anti-inflammatory: IL-10, TGF-β limit excessive inflammation
- TREM2-DAP12 signaling: Triggers phagocytosis of amyloid, cellular debris
- Complement-mediated phagocytosis: C3b opsonization, CR3 receptor recognition
- **LC3-associated phagocytosis (LAP): ** Non-canonical autophagy for phagolysosome formation
- Aerobic glycolysis: Switch to Warburg-like metabolism for immune activation
- Oxidative burst: NADPH oxidase (NOX2) produces ROS for microbial killing
- Mitochondrial dynamics: Fusion/fission alterations in disease states
- DAM (Disease-Associated Microglia): TREM2-dependent transcriptional response to amyloid
- TREM2 variants: Risk alleles (R47H, R62H) impair phagocytosis
- Amyloid clearance: Reduced ability to clear Aβ plaques
- α-Synuclein recognition: TLR2, TLR4 detect Lewy bodies
- Neuroinflammation: Chronic microglial activation, dopaminergic neuron loss
- LRRK2 mutations: G2019S enhances microglial inflammatory response
flowchart TD
A["Resting Microglia<br/>S"urveillance State"] -->|"Aβ/α-Syn Pathology"| B["DAM Stage 1<br/>Disease-Associated"]
B -->|"Continued Pathology"| C["DAM Stage 2<br/>Neurotoxic"]
C -->|"Chronic Activation"| D["M1 Pro-inflammatory<br/>TNF-α, IL-1β, I"L-6"]
A -->|"Anti-inflammatory Signals"| E["M2 Anti-inflammatory<br/>IL-10, TGF-β"]
E -->|"Resolution"| F["Tissue Repair"]
G["AD Pathology"] -->|"Amyloid-β"| H["Microglial Activation"]
H -->|"Chronic"| I["Neuroinflammation"]
I -->|"Synapse Loss"| J["Cognitive Decline"]
K["PD Pathology"] -->|"α-Synuclein"| H
H -->|"NLRP3 Inflammasome"| LIL-1β R["elease"]
L --> M["Nigral Neuron Death"]
style A fill:#e8f5e9
style D fill:#ffcdd2
style I fill:#ffcdd2
style M fill:#ef9a9a
¶ Key Genes and Proteins
Microglia function is regulated by numerous genes and proteins:
| Gene/Protein |
Function |
Disease Relevance |
| TREM2 |
Triggering receptor on myeloid cells 2; triggers microglial activation |
AD risk gene; TREM2 R47H increases AD risk ~3x |
| CX3CR1 |
Fractalkine receptor; regulates microglial surveillance |
Parkinson's disease; promotes neuroprotection |
| CD33 |
Sialic acid-binding immunoglobulin-like lectin; modulates phagocytosis |
AD risk gene; CD33 associated with reduced amyloid clearance |
| CR1 |
Complement receptor 1; mediates complement activation |
AD risk gene; linked to tau pathology |
| PLD3 |
Phospholipase D3; regulates lysosomal function |
AD risk gene; rare variants increase risk |
| ABCA7 |
ATP-binding cassette transporter A7; lipid transport |
AD risk gene; affects amyloid clearance |
| SORL1 |
Sortilin-related receptor; vesicle trafficking |
AD risk gene; affects APP processing |
| IL1A |
Interleukin-1 alpha; pro-inflammatory cytokine |
Enhanced in AD and PD |
| IL1B |
Interleukin-1 beta; major inflammatory mediator |
Elevated in neurodegeneration |
| TNF |
Tumor necrosis factor alpha; inflammatory signaling |
Elevated in AD, PD, ALS |
| CCL2 |
CC chemokine ligand 2; monocyte recruitment |
Recruits microglia to pathology sites |
| CXCL10 |
Chemokine CXCL10; inflammatory chemokine |
Elevated in MS and AD |
Microglia represent key therapeutic targets in neurodegenerative diseases:
- TREM2 agonists: Enhance microglial phagocytosis and amyloid clearance
- CSF1R inhibitors: Deplete pro-inflammatory microglia (trial in AD)
- CD33 inhibitors: Block inhibitory CD33 to enhance clearance
- CX3CR1 modulators: Enhance fractalkine signaling for neuroprotection
- Anti-inflammatory agents: Minimize chronic microglial activation
- NLRP3 inflammasome inhibitors: Target IL-1β production
- Minocycline: Antibiotic with anti-inflammatory properties (trial in PD, AD)
- P2X7 antagonists: Target microglial P2X7 receptor for anti-inflammatory effects
- Microglial replacement: iPSC-derived microglia transplantation
- Gene therapy: Deliver neurotrophic factors via microglia-targeted vectors
- Brain-penetrant immunomodulators: Next-generation anti-inflammatory drugs
Microglia interact with multiple AD-relevant pathways:
- Amyloid-beta clearance: TREM2-mediated phagocytosis
- Neuroinflammation: NF-κB, MAPK signaling cascades
- Complement activation: C1q, C3-mediated synapse elimination
- Tau pathology spread: Microglial transport of tau seeds
- Alpha-synuclein clearance: Impaired TLR-mediated recognition
- Neuroinflammation: Chronic TNF-α, IL-1β release
- Oxidative stress: NADPH oxidase activation
- Mitochondrial dysfunction: LRRK2 G2019S variant effects
- Non-cell autonomous toxicity: Astrocyte-microglia crosstalk
- Excitotoxicity: Glutamate transporter dysfunction
- Oxidative stress: SOD1 mutant effects
- Demyelination: Active phagocytosis of myelin
- Blood-brain barrier: Peripheral immune cell recruitment
- TREM2 variants: Similar to AD risk profile
- Progranulin deficiency: Lysosomal dysfunction
| Pathway |
Role in Microglia |
Therapeutic Target |
| TREM2-DAP12 signaling |
Phagocytosis, survival |
TREM2 agonists |
| NF-κB signaling |
Inflammation |
JAK inhibitors |
| cGAS-STING pathway |
Type I interferon response |
STING inhibitors |
| PPAR-γ signaling |
Anti-inflammatory |
PPAR agonists |
- TREM2 monoclonal antibodies: Enhancing phagocytosis
- CSF1R inhibitors: Reducing microglial proliferation
- BTK inhibitors: Limiting inflammatory activation
- Microglial iPSC transplantation: Cell replacement therapy
- Gene editing: Correcting TREM2 variants
- Nanoparticle drug delivery: Targeted anti-inflammatory therapy
| Gene |
Variant |
Effect on Microglia |
Disease Association |
| TREM2 |
R47H, R62H |
Impaired phagocytosis |
AD (3-4x risk) |
| CD33 |
rs3865444 |
Increased expression |
AD |
| PLCG2 |
M28L |
Altered signaling |
AD |
| ABI3 |
W262 |
Reduced phagocytosis |
AD |
| LRRK2 |
G2019S |
Enhanced inflammation |
PD |
| GBA1 |
N370S |
Lysosomal dysfunction |
PD |
Microglial activation biomarkers:
- TSPO PET imaging: In vivo microglial activation
- CSF YKL-40: Chitinase-3-like protein 1
- CSF sTREM2: Soluble TREM2 fragment
- IL-1β, IL-6, TNF-α: Pro-inflammatory cytokines
- Primary cultured microglia: Rodent and human
- iPSC-derived microglia: Patient-specific models
- CX3CR1-GFP mice: In vivo imaging
- TREM2 knock-out mice: Genetic loss-of-function
- 5xFAD mice: Amyloid model with microglial changes
- α-Syn preformed fibrils: PD model
- Single-cell profiling of human microglia across disease states
- Spatial transcriptomics of microglia in situ
- Development of brain-penetrant microglial modulators
- Understanding microglial heterogeneity in different brain regions